Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies

Ex-Pfizer R&D chief moves to VC PureTech

This article was originally published in Scrip

Executive Summary

Dr John LaMattina, former president of Pfizer's global R&D operations, has joined the Boston, Massachusetts-based venture capital firm PureTech Ventures as a senior partner. Dr LaMattina spent 30 years at Pfizer, retiring in 2007, and was involved with the development of Tarceva (erlotinib), Chantix (varenicline), Zoloft (sertraline), Lyrica (pregabalin) and Selzentry (maraviroc). PureTech also promoted Dr Eric Elenko and Steve Muniz to partners.

Table

View full table

Topics

Related Companies

Tags:
Companies
Latest Headlines

AbbVie Claims Rinvoq Superiority To Dupixent In AD

Merck Investors Keeping A Close Watch On Winrevair Uptake

‘It’s Not About Me’ – AstraZeneca’s Soriot Says His Pay Rise Will Help European Pharma

Executives On The Move: Three New CEOs Among This Week's Changes

See All
UsernamePublicRestriction

Register

SC005501

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By